Johnson & Johnson (JNJ +1%) doesn't expect to receive new supplies of its Doxil cancer drug...


Johnson & Johnson (JNJ +1%) doesn't expect to receive new supplies of its Doxil cancer drug from contract manufacturer Ben Venue Labs until late 2012 at the earliest, following the suspension of manufacturing at an Ohio Ben Venue plant. Shortages of Doxil have existed for the last 6 months thanks to Ben Venue's troubles - J&J says it will "pursue other options" to make Doxil available.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs